Les Meilleures Cliniques et Coûts des traitements des tumeurs neuroendocrines pancréatiques en Ukraine 2026

Accurate pancreatic neuroendocrine tumor diagnosis requires pathological confirmation through biopsy. Specialists use endoscopic ultrasound-guided fine-needle aspiration to obtain tissue. This determines the Ki-67 proliferation index and tumor differentiation. Doctors also use 68Ga-DOTATATE PET/CT scans to identify small lesions and receptor density.

• Pathological assessment: Biopsy remains the gold standard for determining tumor grade.
• Ki-67 index: This marker measures cell division to distinguish low-grade from aggressive tumors.
• Immunohistochemistry: Staining for chromogranin A confirms the neuroendocrine nature of the cells.
• Molecular imaging: Functional PET/CT scans detect small lesions missed by traditional CT scans.

Bookimed Expert Insight: Ukrainian clinics like Dobrobut Medical Network manage over 330,000 patients annually. High patient volumes often correlate with better diagnostic accuracy for rare tumors. For complex cases, choosing surgeons like Dr. Rostyslav Valikhnovskyi provides access to expertise gained from 15,000+ procedures. This depth of experience helps in tailoring diagnostic paths for non-functional tumors.

Patient Consensus: Patients emphasize that a pathology report must include the exact tumor grade. Many recommend an expert pathology reread before starting any treatment plan.

Effective treatment for pancreatic neuroendocrine tumors in Ukraine includes surgical resection for curative results. Specialist centers in Kyiv and Uzhhorod utilize NanoKnife for tumor ablation and CyberKnife radiotherapy. Advanced cases are managed with Actinium-225 targeted radionuclide therapy and systemic molecular drugs.

• Surgical resection: Surgeons perform Whipple procedures or distal pancreatectomies for localized tumors.
• Ablation technology: NanoKnife irreversible electroporation targets tumors while protecting surrounding vital blood vessels.
• Precision radiotherapy: CyberKnife systems deliver high-dose radiation to treat advanced or non-operable lesions.
• Targeted therapy: Actinium-225 therapy provides a molecular biological approach for metastasized neuroendocrine cases.

Bookimed Expert Insight: Quality of care in Ukraine is highly centralized in private networks like Dobrobut, which serves 330,000 patients annually. While many seek surgery, the 11,000 yearly operations performed there suggest high surgical proficiency. Patients can access top-tier expertise from surgeons like Dr. Rostyslav Valikhnovskyi, who has performed over 15,000 procedures.

Patient Consensus: Patients note that getting an accurate pathology report with a Ki-67 index is the most crucial step before surgery. They emphasize finding a center where oncologists and surgeons work together to avoid fragmented care.

Specialized multidisciplinary pNET treatment in Ukraine is centered in Kyiv and Lviv. Leading institutions like Dobrobut Medical Network integrate surgical oncology and advanced techniques. Facilities adhere to ISO standards for quality care. These centers offer complex hepatopancreatobiliary surgery and nuclear medicine.

• Available technologies: Centers utilize CyberKnife and NanoKnife for precise tumor targeting.
• Surgical expertise: Surgeons perform complex procedures like enucleation of pancreatic tumors.
• Advanced therapies: Specialized centers provide Actinium-225 therapy for progressive neuroendocrine cases.
• High-volume care: Major networks treat over 330,000 patients and perform 11,000 operations annually.

Bookimed Expert Insight: Ukrainian private networks offer deep expertise with doctors like Dr. Rostyslav Valikhnovskyi performing over 15,000 operations. Large networks provide 18 specialized departments in one location. This centralization is vital because rare tumors require immediate coordination between surgeons and oncologists. Seeking centers with high surgical volumes ensures teams have the experience needed for technically demanding pancreatic procedures.

Patient Consensus: Patients emphasize that multidisciplinary tumor boards are essential for rare tumors. They note that getting a second pathology review of the Ki-67 index often changes the final treatment plan.

Surgery is the primary and only potentially curative treatment for localized pancreatic neuroendocrine tumors. Resection offers the best chance for long-term recovery when the disease is confined. Surgical options include tumor enucleation or major pancreatectomy depending on size, grade, and tumor location.

• Curative potential: Complete surgical resection remains the only definitive approach for long-term curative outcomes.
• Surgical techniques: Specialists utilize enucleation for small tumors or complex pancreatectomy for larger masses.
• Treatment drivers: Tumor grade and Ki-67 index determine if surgery provides a complete cure.
• Active surveillance: Small, non-functional tumors may be monitored if immediate surgery carries high risks.

Bookimed Expert Insight: Ukraine offers high-volume surgical expertise at centers like Dobrobut Medical Network, which performs over 11,000 operations annually. Patients should note that localized tumors require specialized staging because vessel invasion can change a tumor from resectable to borderline. Choosing a center with ISO certification ensures international quality standards for these complex pancreatic procedures.

Patient Consensus: Patients emphasize that localized does not always mean simple. Many recommend asking for the Ki-67 grade early because it significantly impacts whether surgery alone is sufficient.

Pancreatic neuroendocrine tumors (pNETs) respond effectively to chemotherapy, unlike other neuroendocrine types. Doctors prescribe it for advanced, high-grade, or rapidly progressive disease. It is a vital tool for debulking bulky tumors or managing metastatic spread to the liver when other therapies fail.

• Tumor grade: Grade 3 neuroendocrine carcinomas require aggressive platinum-based chemotherapy as first-line treatment.
• Progression speed: Experts use chemotherapy if tumors grow significantly within 6 to 12 months.
• Specific regimens: CAPTEM (capecitabine and temozolomide) is preferred for advanced, low-grade pancreatic NETs.
• Surgical preparation: Neoadjuvant chemotherapy shrinks large tumors to make surgical removal possible and safer.

Bookimed Expert Insight: While many oncology centers focus only on standard IV chemotherapy, leading Ukrainian networks like Dobrobut Medical Network integrate multiple surgical and high-tech options. Large private networks in Kyiv perform over 11,000 operations annually, often combining systemic chemotherapy with precise interventions like CyberKnife or NanoKnife. This high surgical volume suggests that chemotherapy in these centers is frequently used as a strategic bridge to surgery rather than just a palliative measure.

Patient Consensus: Patients emphasize that the pathology report, specifically the Ki-67 index, is the most important factor for success. Many note that CAPTEM can show strong results even when conventional chemotherapy was initially dismissed as ineffective.

Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium-177 is available in Ukraine for treating somatostatin receptor-positive pancreatic neuroendocrine tumors. Specialized oncology centers in Kyiv utilize this systemic therapy for metastatic or inoperable pNETs. Treatment eligibility requires confirmation of receptor expression through Ga68-DOTATATE PET scans.

• Treatment focus: Uses radioactive Lutetium-177 combined with synthetic somatostatin.
• Mandatory imaging: Ga68-DOTATATE PET/CT scans must confirm receptor uptake.
• Clinical setting: Delivered in tertiary centers with certified nuclear medicine departments.
• Therapy cycle: Administered as systemic treatment for metastatic GEP-NET cases.

Bookimed Expert Insight: Ukraine ranks 4th globally in our network for oncology requests, reflecting significant clinical capacity. While large networks like Dobrobut Medical Network manage over 330,000 patients annually, nuclear therapies require specific licensing. Patients should verify a facility has both the radiopharmaceutical supply and dedicated radiation-safety beds before traveling.

Patient Consensus: Patients note that confirming receptor-positive status on imaging is the first essential step. They often emphasize that PRRT is a multi-cycle process requiring careful blood count and kidney monitoring between treatments.

Liver metastases from pNETs are managed through liver-directed therapies and systemic treatments when surgery is not feasible. Specialized Ukrainian centers utilize CyberKnife and NanoKnife for precision tumor destruction. Doctors also employ somatostatin analogs, targeted therapies, and peptide receptor radionuclide therapy (PRRT) to stabilize growth and control symptoms.

• Liver-directed therapy: Targeted procedures like radiofrequency ablation destroy small tumors using heat.
• Advanced radiation: CyberKnife delivers high-dose radiation to specific lesions, sparing healthy tissue.
• Systemic control: Lanreotide or octreotide injections help manage hormone symptoms and tumor progression.
• Nanoknife technology: Irreversible electroporation uses electrical pulses to treat tumors near sensitive vessels.

Bookimed Expert Insight: Ukraine offers high-volume surgical expertise at centers like Dobrobut Medical Network in Kyiv. Their staff performs over 11,000 annual operations within ISO-certified facilities. Large networks often provide diagnostic speed that smaller clinics lack. Coordination between oncology and endovascular departments is essential for effective chemoembolization protocols.

Patient Consensus: Patients emphasize the importance of symptom management over pure imaging results. Many note that controlling flushing and abdominal pain significantly improves daily quality of life.